Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
CVS data by YCharts
CVS (CVS) and Target (TGT): Cramer spoke with CVS Health President and CEO Larry Merlo and Target CEO Brian Cornell to dig deeper into CVS' acquisition of Target's pharmacy and clinic business. Target is a holding in Cramer's charitable trust, Action Alerts PLUS.
Cornell said the partnership will strengthen Target's position in the wellness space with an expert that brings scale, experience and capabilities. Cornell said the CVS portion of his stores will operate as a store-within-a-store and have the look and feel of a CVS pharmacy. More than 1,660 Target pharmacies in 47 states will be rebranded as CVS pharmacies.
This deal expands CVS' presence in new markets, Merlo told Cramer, and said that while there may be some one-time costs in the short term, the transaction will be at least 12 cents accretive in 2018 and beyond. Cornell added the deal is all about growth and expects the deal to drive traffic to Target stores and return cash to shareholders. In addition, the deal allows Target to increase focus on its signature product categories.
TWTR data by YCharts
Twitter (TWTR): Is Twitter whistling past the graveyard? Cramer is frustrated the social media company, another AAP holding, might kill the golden goose out of arrogance, mismanagement and a mistaken belief that it's always going to be the only game in town. Cramer's not so sure about that anymore.
Twitter's stock is down nearly 26% in the last three months. While Cramer is happy to see former CEO Dick Costello on the way out, he'll remain on the board. Leaving Costolo on the board is a signal that Twitter doesn't truly believe anything is wrong.
ESRX data by YCharts
Express Scripts (ESRX): This pharmacy benefits manager, another AAP holding, is the largest in its sector. Cramer thinks the company's long-term fundamentals are perfect because its market share is simply too big, especially on expensive new drugs. By 2018, expensive specialty medicines will account for roughly half of all prescription drug spending, Cramer said.
ESRX is powered by some tremendous long-term themes given our aging population. Its market share means it may be the most powerful company we have for containing the rising cost of prescription drugs. He advises buying it into any short-term weakness for the long term.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.